Stay updated on Pembrolizumab for Genomic Instability Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Genomic Instability Clinical Trial page.

Latest updates to the Pembrolizumab for Genomic Instability Clinical Trial page
- Check6 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check13 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAccess to the study page now returns a 403 Forbidden error, replacing the previously loaded study record details. This change blocks viewing core trial information, documents, and contact/location data.SummaryDifference19%

- Check55 days agoChange DetectedThe revision entry for the Study Protocol and Statistical Analysis Plan was updated from v3.6.5 to v3.6.6, indicating a newer version of the document is now linked on the study record.SummaryDifference0.1%

- Check76 days agoChange DetectedThe page now displays Revision: v3.6.5, replacing the previous Revision: v3.6.4. This reflects a small maintenance update to the page metadata.SummaryDifference0.1%

- Check90 days agoChange DetectedThe page's revision line was updated to v3.6.4, indicating a software release rather than changes to study details. This appears to be a backend update without substantive changes to the trial information.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Genomic Instability Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Genomic Instability Clinical Trial page.